SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-042449
Filing Date
2023-11-22
Accepted
2023-11-22 13:55:18
Documents
18
Period of Report
2023-11-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 48560
2 ex10-1.htm EX-10.1 215041
3 ex10-2.htm EX-10.2 154551
4 ex10-3.htm EX-10.3 142904
5 ex10-4.htm EX-10.4 183822
6 ex10-5.htm EX-10.5 117747
7 ex10-6.htm EX-10.6 40486
  Complete submission text file 0001493152-23-042449.txt   1254818

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE vtro-20231116.xsd EX-101.SCH 3033
9 XBRL LABEL FILE vtro-20231116_lab.xml EX-101.LAB 34240
10 XBRL PRESENTATION FILE vtro-20231116_pre.xml EX-101.PRE 22371
12 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3082
Mailing Address 4621 TECHNOLOGY DRIVE GOLDEN CO 80403
Business Address 4621 TECHNOLOGY DRIVE GOLDEN CO 80403 (720) 859-4120
Vitro Biopharma, Inc. (Filer) CIK: 0000793171 (see all company filings)

IRS No.: 841012042 | State of Incorp.: NV | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 001-41766 | Film No.: 231432688
SIC: 2836 Biological Products, (No Diagnostic Substances)